Blowout in PBS cost of novel anticoagulant

DUSC, a PBAC committee, began its review into the use of NOACs for non-atrial fibrillation indications last year, following extension of the indication to include treatment of deep vein thrombosis (DVT), prevention of venous thromboembolism (VTE) and treatment of pulmonary embolism (PE) in patients who have undergone knee or hip replacement surgeries.

According to the committee report, prescriptions for rivaroxaban – the first of the NOACs to receive approval for the expanded indication – began to increase in December 2012,